Trimetazidine

Trimetazidine
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	C01EB15 (WHO) ;
Legal status
Legal status	UK: Controlled Drug;
Pharmacokinetic data
Bioavailability	completely absorbed at around 5 hours, steady state is reached by 60th hour
Protein binding	low (16%)
Metabolism	minimal
Elimination half-life	7 to 12 hours
Excretion	mainly renal (unchanged), exposure is increased in renal impairment – on average by four-fold in subjects with severe renal impairment (CrCl <30 ml/min)
Identifiers
	IUPAC name 1-(2,3,4-trimethoxybenzyl)piperazine;
CAS Number	5011-34-7 ;
PubChem CID	21109;
ChemSpider	19853 ;
UNII	N9A0A0R9S8;
ChEMBL	ChEMBL203266 ;
CompTox Dashboard (EPA)	DTXSID2048531 ;
ECHA InfoCard	100.023.355
Chemical and physical data
Formula	C14H22N2O3
Molar mass	266.341 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O(c1ccc(c(OC)c1OC)CN2CCNCC2)C;
	InChI InChI=1S/C14H22N2O3/c1-17-12-5-4-11(13(18-2)14(12)19-3)10-16-8-6-15-7-9-16/h4-5,15H,6-10H2,1-3H3 ; Key:UHWVSEOVJBQKBE-UHFFFAOYSA-N ;
	(what is this?) (verify)

Trimetazidine (IUPAC: 1-(2,3,4-trimethoxybenzyl)piperazine) is a drug for angina pectoris (chest pain associated with blood flow to the heart) sold under many brand names. Trimetazidine is described as the first cytoprotective anti-ischemic agent developed and marketed by Laboratoires Servier (France). It is an anti-ischemic (antianginal) metabolic agent of the fatty acid oxidation inhibitor class, meaning that it improves myocardial glucose utilization through inhibition of fatty acid metabolism.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.